Fosdenopterin (Nulibry) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Breakthrough Therapy FDA Priority Review FDA
AACT PubChem

Active Ingredient History

NOW
  • Now
CPMP may refer to:Committee for Proprietary Medicinal Products Certified Project Management Professional Core-Plus Mathematics Project Cyclic pyranopterin monophosphate or fosdenopterin Commissioning Process Management Professional (ASHRAE)   Wikipedia

Chemistry

  • SMILES: Nc1nc(=O)c2c([nH]1)N[C@@H]1O[C@@H]3COP(=O)(O)O[C@@H]3C(O)(O)[C@@H]1N2
  • InChIKey: CZAKJJUNKNPTTO-AJFJRRQVSA-N
  • Mol. Mass: 363.22
  • ALogP: -2.52
  • ChEMBL Molecules:
    fosdenopterin  
    fosdenopterin hydrobromide  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

alxn1101 | cpmp | cyclic pyranopterin monophosphate

Organizations (7)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (2)


 

Metal Metabolism, Inborn Errors

Molybdenum (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Genetic Diseases, Inborn (Phase 1)

Molybdenum Cofactors (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue